Reaserch Advances on Induction of Fetal Hemoglobin (HbF) by Drugs in the Treatment of β-Thalassemia--Review.
10.19746/j.cnki.issn.1009-2137.2020.04.059
- Author:
Li LI
1
;
Zhi-Qiang SUN
2
Author Information
1. Department of Hematology, Shenzhen Hospital, Southern Medical University, Shenzhen 518110, Guangdong Province, China.The Third School of Clinical Medicine, Southern Medical University, Guangzhou 510515, Guangdong Province, China.
2. Department of Hematology, Shenzhen Hospital, Southern Medical University, Shenzhen 518110, Guangdong Province, China.The Third School of Clinical Medicine, Southern Medical University, Guangzhou 510515, Guangdong Province, China E-mail: zhqsun69@163.com.
- Publication Type:Journal Article
- MeSH:
Blood Transfusion;
Fetal Hemoglobin;
Humans;
Hydroxyurea;
beta-Globins;
beta-Thalassemia
- From:
Journal of Experimental Hematology
2020;28(4):1424-1428
- CountryChina
- Language:Chinese
-
Abstract:
β-thalassaemias are inherited hemoglobin disorders caused by defects in the β-globin gene. In recent years, researches have re-mentioned the therapeutic significance of drug-induced fetal hemoglobin (HbF), which can reduce the imbalance of α and β chains and improve the severity of anemia by increasing the expression of γ chain. Drug trials, such as hydroxyurea, thalidomide and desitabine have shown elevated hemoglobin, decreased blood transfusion dependence, and reduced symptoms other than anemia after treatment. In addition, in vitro experiments suggested that HbF can also induce by other drugs, which providing important clues for safe and effective HbF inducers. Therefore, this article reviews the current research progress so as to expect beneficial to clinical treatment.
